Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio (NYSE: NUVB), a global oncology company, announced its leadership team's participation in three upcoming investor conferences in May 2025.

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/12/2025 - 04:05 PM EDT

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at three upcoming investor conferences:

H.C. Wainwright 3^rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 3:00 p.m. ET in New York, NY

2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 p.m. ET in New York, NY

TD Cowen 6^th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 28, 2025, at 3:30 p.m. ET (virtual)

Live webcasts of each presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following each event.

About Nuvation Bio

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment by developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib, a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-1511, an innovative drug-drug conjugate (DDC) designed for targeted cancer treatment; and NUV-868, a BD2-selective BET inhibitor.

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250512721886/en/

Nuvation Bio Investor Contact:
ir@nuvationbio.com

Nuvation Bio Media Contact:
media@nuvationbio.com

Source: Nuvation Bio Inc.

Keep reading

More on NUVB

All NUVB news

Trending in the feed

GUTS

Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation Open the live feed